The latest update is out from CStone Pharmaceuticals ( (HK:2616) ).
CStone Pharmaceuticals announced that its CEO and executive director, Dr. Jianxin Yang, has increased his shareholding in the company by purchasing an additional 560,000 shares, bringing his total to 10,359,000 shares. This move signifies Dr. Yang’s confidence in the company’s future prospects and his commitment to its growth and stability in a challenging market environment.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focused on developing anti-cancer therapies. The company addresses unmet medical needs in China and globally, having launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. CStone’s pipeline includes 16 promising candidates, featuring potentially first-in-class or best-in-class therapies, and is supported by a management team with extensive drug development experience.
YTD Price Performance: -4.35%
Average Trading Volume: 5,667,433
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.89B
See more data about 2616 stock on TipRanks’ Stock Analysis page.